A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial

• Published in: International journal of radiation oncology, biology, physics Vol. 106; no. 1; pp. 116 - 123
• Main Authors: Pasquier, David, Peiffert, Didier, Nickers, Philippe, Maingon, Philippe, Pommier, Pascal, Lacornerie, Thomas, Martinage, Geoffrey, Tresch, Emmanuelle, Lartigau, Eric
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2020; Elsevier
• Subjects: Aged; Aged, 80 and over; Erectile Dysfunction - epidemiology; Fiducial Markers; Humans; Life Sciences; Male; Middle Aged; Organs at Risk - radiation effects; Outcome Assessment, Health Care; Prevalence; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - mortality; Prostatic Neoplasms - radiotherapy; Radiation Dose Hypofractionation; Radiosurgery - adverse effects; Radiosurgery - instrumentation; Radiosurgery - methods; Radiosurgery - mortality; Re-Irradiation - adverse effects; Re-Irradiation - methods; Rectum - radiation effects; Time Factors; Treatment Outcome; Urinary Bladder - radiation effects; Urination Disorders - epidemiology
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/j.ijrobp.2019.09.039

The aim of this analysis was to assess the 5-year tolerance and survival in patients undergoing hypofractionated stereotactic boost after external beam radiation therapy (EBRT) for intermediate-risk prostate cancer. Between August 2010 and April 2013, 76 patients with intermediate-risk prostate carcinoma were included in the study. A first course delivered 46 Gy using conventional fractionation. The second course delivered a boost of 18 Gy (3 × 6 Gy) within 10 days using stereotactic body radiation therapy (SBRT). Gastrointestinal and genitourinary toxicities were assessed according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events v4.0. Secondary outcome measures were overall, biochemical relapse–free, and relapse-free survival; prostate-specific antigen kinetics; and patient functional status (urinary and sexual) according to the International Index of Erectile Function and International Prostate Symptom Score questionnaires. Sixty patients (79%) were treated by CyberKnife and 16 (21%) by linear accelerator. Median follow-up was 62 months (range, 29-69). The cumulative incidence of genitourinary and gastrointestinal grade ≥2 toxicities at month 60 after the end of radiation therapy was 1.4% (95% confidence interval [CI], 0.1%-6.6%) and 9.3% (95% CI, 4.1%-17.1%), respectively. Biochemical relapse–free and relapse-free survival rates at 5 years were 87.4% (95% CI, 77.1%-93.2%) and 86.2% (95% CI, 75.8-92.3), respectively. The mean (standard deviation) prostate-specific antigen variation within 3 months and 5 years post–radiation therapy was –1.20 ng/mL/mo (0.79) and –1.30 ng/mL/y (1.05), respectively. There was no significant difference between the International Prostate Symptom quality of life score between inclusion and month 60. For the International Index of Erectile Function, there was a significant difference between inclusion and month 60 (P = .005), with a higher proportion of severe/noninterpretable disorders at 60 months. The results of the trial demonstrate that the EBRT and SBRT combination is well tolerated and yields good efficacy results. These data provide a good basis for comparing EBRT and brachytherapy boost to EBRT and SBRT boost in future prospective studies.